Neisseria gonorrhoeae Antimicrobial Resistance Among Men Who Have Sex With Men and Men Who Have Sex Exclusively With Women: The Gonococcal Isolate Surveillance Project, 2005–2010

BACKGROUND Gonorrhea treatment has been complicated by antimicrobial resistance in Neisseria gonorrhoeae. Gonococcal fluoroquinolone resistance emerged more rapidly among men who have sex with men (MSM) than men who have sex exclusively with women (MSW). OBJECTIVE To determine whether N. gonorrhoeae urethral isolates from MSM were more likely than isolates from MSW to exhibit resistance to or elevated minimum inhibitory concentrations (MICs) of antimicrobials used to treat gonorrhea. DESIGN 6 years of surveillance data from the Gonococcal Isolate Surveillance Project. SETTING Publicly funded sexually transmitted disease clinics in 30 U.S. cities. PATIENTS Men with a total of 34 600 episodes of symptomatic urethral gonorrhea. MEASUREMENTS Percentage of isolates exhibiting resistance or elevated MICs and adjusted odds ratios for resistance or elevated MICs among isolates from MSM compared with isolates from MSW. RESULTS In all U.S. regions except the West, isolates from MSM were significantly more likely to exhibit elevated MICs of ceftriaxone and azithromycin than isolates from MSW (P < 0.050). Isolates from MSM had a high prevalence of resistance to ciprofloxacin, penicillin, and tetracycline and were significantly more likely to exhibit antimicrobial resistance than isolates from MSW (P < 0.001). LIMITATIONS Sentinel surveillance may not be representative of all patients with gonorrhea. HIV status, travel history, and antimicrobial use data were missing for some patients. CONCLUSION Men who have sex with men are vulnerable to the emerging threat of antimicrobial-resistant N. gonorrhoeae. Because antimicrobial susceptibility testing is not routinely done in clinical practice, clinicians should monitor for treatment failures among MSM diagnosed with gonorrhea. Strengthened prevention strategies for MSM and new antimicrobial treatment options are needed.

[1]  K. Holmes,et al.  Emergence of increased azithromycin resistance during unsuccessful treatment of Neisseria gonorrhoeae infection with azithromycin (Portland, OR, 2011). , 2012, Sexually transmitted diseases.

[2]  J. Papp,et al.  Update to CDC's Sexually transmitted diseases treatment guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections. , 2012, MMWR. Morbidity and mortality weekly report.

[3]  K. Holmes,et al.  Neisseria gonorrhoeae with high-level resistance to azithromycin: case report of the first isolate identified in the United States. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  E. Erbelding,et al.  Changes in fluoroquinolone use for gonorrhea following publication of revised treatment guidelines. , 2012, American journal of public health.

[5]  K. Workowski,et al.  Centers for Disease Control and Prevention Sexually Transmitted Disease Treatment Guidelines. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  M. Unemo,et al.  High-Level Cefixime- and Ceftriaxone-Resistant Neisseria gonorrhoeae in France: Novel penA Mosaic Allele in a Successful International Clone Causes Treatment Failure , 2011, Antimicrobial Agents and Chemotherapy.

[7]  S. Lévesque,et al.  Ciprofloxacin-Resistant Shigella sonnei among Men Who Have Sex with Men, Canada, 2010 , 2011, Emerging infectious diseases.

[8]  M. Unemo,et al.  Is Neisseria gonorrhoeae Initiating a Future Era of Untreatable Gonorrhea?: Detailed Characterization of the First Strain with High-Level Resistance to Ceftriaxone , 2011, Antimicrobial Agents and Chemotherapy.

[9]  Joseph Vyankandondera,et al.  High Human Immunodeficiency Virus Incidence in a Cohort of Rwandan Female Sex Workers , 2011, Sexually transmitted diseases.

[10]  K. Sankar,et al.  Gonorrhoea treatment failures to cefixime and azithromycin in England, 2010. , 2011, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[11]  Neisseria gonorrhoeae with reduced susceptibility to azithromycin--San Diego County, California, 2009. , 2011, MMWR. Morbidity and mortality weekly report.

[12]  Stuart Berman,et al.  Sexually transmitted diseases treatment guidelines, 2010. , 2010, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[13]  M. Unemo,et al.  Two cases of verified clinical failures using internationally recommended first-line cefixime for gonorrhoea treatment, Norway, 2010. , 2010, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[14]  L. Johnson,et al.  The Effect of Genital Tract Infections on HIV-1 Shedding in the Genital Tract: A Systematic Review and Meta-Analysis , 2008, Sexually transmitted diseases.

[15]  W. Mcfarland,et al.  Frequent international travel by men who have sex with men recently diagnosed with HIV-1: potential for transmission of primary HIV-1 drug resistance. , 2008, Journal of travel medicine.

[16]  G. Sensabaugh,et al.  Emergence of Multidrug-Resistant, Community-Associated, Methicillin-Resistant Staphylococcus aureus Clone USA300 in Men Who Have Sex with Men , 2008, Annals of Internal Medicine.

[17]  P. Bloomfield.  Update on emerging infections: news from the Centers for Disease Control and Prevention. Update to CDC's Sexually Transmitted Diseases Treatment Guidelines, 2006: fluoroquinolones no longer recommended for treatment of gonococcal infections. , 2007, Annals of emergency medicine.

[18]  M. Yasuda,et al.  Threat to Cefixime Treatment for Gonorrhea , 2007, Emerging infectious diseases.

[19]  K. Holmes,et al.  Update to CDC's sexually transmitted diseases treatment guidelines, 2006: fluoroquinolones no longer recommended for treatment of gonococcal infections. , 2007, MMWR. Morbidity and mortality weekly report.

[20]  J. Buehler,et al.  Condom Use and Risk of Gonorrhea and Chlamydia: A Systematic Review of Design and Measurement Factors Assessed in Epidemiologic Studies , 2006, Sexually transmitted diseases.

[21]  W. Heneine,et al.  The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. , 2004, The Journal of infectious diseases.

[22]  J. Powers,et al.  Trends in antimicrobial drug development: implications for the future. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  J. Gerberding,et al.  Increases in fluoroquinolone-resistant Neisseria gonorrhoeae among men who have sex with men--United States, 2003, and revised recommendations for gonorrhea treatment, 2004. , 2004, MMWR. Morbidity and mortality weekly report.

[24]  Katsuhisa Endo,et al.  Mosaic-Like Structure of Penicillin-Binding Protein 2 Gene (penA) in Clinical Isolates of Neisseria gonorrhoeae with Reduced Susceptibility to Cefixime , 2002, Antimicrobial Agents and Chemotherapy.

[25]  A. Mckay.  The Circuit Party Men's Health Survey: Findings and Implications for Gay and Bisexual Men , 2001 .

[26]  M. Ferraro.  Performance standards for antimicrobial susceptibility testing , 2001 .

[27]  T. Muratani,et al.  Emergence of cephem- and aztreonam-high-resistant Neisseria gonorrhoeae that does not produce β-lactamase , 2001, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[28]  U. Bauer,et al.  [Centers for Disease Control and Prevention (CDC)]. , 2000, Annales de dermatologie et de venereologie.

[29]  W. Shafer,et al.  Missense mutations that alter the DNA-binding domain of the MtrR protein occur frequently in rectal isolates of Neisseria gonorrhoeae that are resistant to faecal lipids. , 1995, Microbiology.

[30]  R. Ohye,et al.  Emerging in vitro resistance to quinolones in penicillinase-producing Neisseria gonorrhoeae strains in Hawaii , 1994, Antimicrobial Agents and Chemotherapy.

[31]  J. Zenilman,et al.  Frequency and distribution in the United States of strains of Neisseria gonorrhoeae with plasmid-mediated, high-level resistance to tetracycline. , 1987, The Journal of infectious diseases.

[32]  S. Morse,et al.  High-level tetracycline resistance in Neisseria gonorrhoeae is result of acquisition of streptococcal tetM determinant , 1986, Antimicrobial Agents and Chemotherapy.

[33]  D. Fagan.  Comparison of Neisseria gonorrhoeae isolates from homosexual and heterosexual men. , 1985, Genitourinary medicine.

[34]  K. Holmes,et al.  Gonococcal sensitivity to fecal lipids can be mediated by an Mtr-independent mechanism , 1983, Journal of clinical microbiology.

[35]  K. Holmes,et al.  Gonococcal strains from homosexual men have outer membranes with reduced permeability to hydrophobic molecules , 1982, Infection and immunity.

[36]  C. Schofield.  Sexually transmitted disease surveillance. , 1982, British medical journal.

[37]  K. Holmes,et al.  Correlation of A uxo type and Penicillin Susceptibility of Neisseria gonorrhoeae with Sexual Preference and Clinical Manifestations of Gonorrhea , 1980, Sexually transmitted diseases.

[38]  Watson Ra.  Gonorrhea and acute epididymitis. , 1979 .

[39]  P. Piot,et al.  Epidemiology and treatment of penicillinase-producing Neisseria gonorrhoeae. , 1979, Sexually transmitted diseases.

[40]  J. Curran.  Management of Gonococcal Pelvic Inflammatory Disease , 1979, Sexually transmitted diseases.

[41]  R. Watson.  Gonorrhea and acute epididymitis. , 1979, Military medicine.

[42]  J. Martin,et al.  Comparative study of gonococcal susceptibility to penicillin in the United States, 1955-1969. , 1970, The Journal of infectious diseases.